Date Title Description PDF
26 Jul 2023 On P&L The Company releases the press release related to the first half 2023 financial results Download
26 Jul 2023 On P&L The Company releases the first half 2023 financial results presentation Download
26 Jul 2023 On buy-back programmes The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program.   Download
10 May 2023 On P&L The Company releases the first quarter 2023 financial results presentation Download
10 May 2023 On P&L The Company releases the press release related to the first quarter 2023 financial results Download

Pages

Date Title Description PDF
03 Nov 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 27 October and 2 November 2023 Download
27 Oct 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 20 October and 26 October 2023 Download
20 Oct 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 13 October and 19 October 2023 Download
13 Oct 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 6 October and 12 October 2023 Download
06 Oct 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 29 September and 5 October 2023 Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages